Portfolio Company News

Cognition Therapeutics has a transformative 2021 with positive performance addressing age related degenerative diseases and disorders of the central nervous system.

by | Jan 10, 2022 | Portfolio Company News

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.…

Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

by | Nov 3, 2021 | Portfolio Company News

PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced the addition of Ellen B.…

Sofia Fund Portfolio Earns Returns as Two Portfolio Companies Move to Next Stage of Growth

by | Oct 25, 2021 | Portfolio Company News

Cognitive Therapeutics goes public, Explorer Surgical acquired

MINNEAPOLIS (Oct. 25, 2021) – Sofia Fund, the angel investment firm focused exclusively on women-led companies, announces new milestones: two of its portfolio companies have progressed onto their next stages of growth, providing returns for Sofia’s group of investors.…

Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data

by | May 10, 2020 | Portfolio Company News

Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660.

This is a major milestone in Rebiotix’s efforts to bring the first microbiota-based therapeutic to the market to treat people that have recurrent Clostridioides difficile infection (rCDI).…